Eisai Begins Marketing Diabetes II Drug in China

Eisai Pharma announced it has begun China marketing of Glufast®, a phenylalanine derived rapid-acting insulin secretagogue that stimulates insulin production. In 2007, Eisai in-licensed rights to sell Glufast in 10 ASEAN countries from Kissei Pharmaceutical Co., which discovered and developed the drug. It was approved by the SFDA in November 2009. More details.... Stock Symbol: (TSE: 4523)